Hims & Hers Health Inc. stock surged on news of potential FDA leadership changes. The company may benefit from this with a positive outlook, despite facing challenges with their GLP-1 drugs. Analysts are cautious, with varied opinions on the stock.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing